Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
News|Articles|November 5, 2026
FAQ: What FDA’s Individualized Gene Editing Draft Guidance Means for Developers
Author(s)Emily Schoenthaler
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) has proposed a regulatory framework that would allow sponsors to include multiple patient-specific variants of a genome editing (GE) product in a single biologics license application (BLA). Issued by the Center for Biologics Evaluation and Research (CBER) on October 27, 2026, the draft guidance, Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management, describes how sponsors could establish boundaries for product variation and use in vitro evidence to support additional variants after approval. Comments are due November 27, 2026.¹⁻³
Related to this article
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
The half-life-extended antibody failed its primary endpoints in two Phase 2 SKYWAY sub-studies, so Spyre is dropping it in rheumatic diseases and moving it into a combination trial in hidradenitis suppurativa.
Advertisement
Advertisement